Potent and selective activity of a new carbocyclic nucleoside analog (Carbovir: NSC 614846) against human immunodeficiency virus In vitro

Robert Vince; Mei Hua; Jay Brownell; Susan Daluge; Fangchen Lee; William M. Shannon; George C. Lavelle; Jeanine Qualls; Owen S. Weislow; Rebecca Kiser; Peter G. Canonico; Robert H. Schultz; V. L. Narayanan; Joseph G. Mayo; Robert H. Shoemaker; Michael R. Boyd

doi:10.1016/S0006-291X(88)80950-1

Potent and selective activity of a new carbocyclic nucleoside analog (Carbovir: NSC 614846) against human immunodeficiency virus In vitro

Robert Vince, Mei Hua, Jay Brownell, Susan Daluge, Fangchen Lee, William M. Shannon, George C. Lavelle, Jeanine Qualls, Owen S. Weislow, Rebecca Kiser, Peter G. Canonico, Robert H. Schultz, V. L. Narayanan, Joseph G. Mayo, Robert H. Shoemaker, Michael R. Boyd

Center for Drug Design

Research output: Contribution to journal › Article › peer-review

226 Scopus citations

Abstract

Carbocyclic 2′,3′-didehydro-2′,3′-dideoxyguanosine (Carbovir: NSC 614846), a novel nucleoside analog, emerged as a potent and selective anti-HIV agent from a large screening program conducted by the National Cancer Institute and its contractors. Its hydrolytic stability and its ability to inhibit the infectivity and replication of HIV in T-cells at concentrations of approximately 200- to 400-fold below toxic concentrations make carbovir a top-priority candidate for development as a potential antiretroviral agent in the treatment of AIDS patients.

Original language	English (US)
Pages (from-to)	1046-1053
Number of pages	8
Journal	Biochemical and Biophysical Research Communications
Volume	156
Issue number	2
DOIs	https://doi.org/10.1016/S0006-291X(88)80950-1
State	Published - Oct 31 1988

Bibliographical note

Funding Information:
This work was supported by NIH grant R01 CA23263, NCl contract NO1-CA-74102, and USAMRIID contract DAMD17-86-C-6013.

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Publisher link

10.1016/S0006-291X(88)80950-1

Find It

Find It at U of M Libraries

Cite this

Vince, R., Hua, M., Brownell, J., Daluge, S., Lee, F., Shannon, W. M., Lavelle, G. C., Qualls, J., Weislow, O. S., Kiser, R., Canonico, P. G., Schultz, R. H., Narayanan, V. L., Mayo, J. G., Shoemaker, R. H., & Boyd, M. R. (1988). Potent and selective activity of a new carbocyclic nucleoside analog (Carbovir: NSC 614846) against human immunodeficiency virus In vitro. Biochemical and Biophysical Research Communications, 156(2), 1046-1053. https://doi.org/10.1016/S0006-291X(88)80950-1

Vince, R, Hua, M, Brownell, J, Daluge, S, Lee, F, Shannon, WM, Lavelle, GC, Qualls, J, Weislow, OS, Kiser, R, Canonico, PG, Schultz, RH, Narayanan, VL, Mayo, JG, Shoemaker, RH & Boyd, MR 1988, 'Potent and selective activity of a new carbocyclic nucleoside analog (Carbovir: NSC 614846) against human immunodeficiency virus In vitro', Biochemical and Biophysical Research Communications, vol. 156, no. 2, pp. 1046-1053. https://doi.org/10.1016/S0006-291X(88)80950-1

@article{4a69e35927b8446eb25df440538a7483,

title = "Potent and selective activity of a new carbocyclic nucleoside analog (Carbovir: NSC 614846) against human immunodeficiency virus In vitro",

abstract = "Carbocyclic 2′,3′-didehydro-2′,3′-dideoxyguanosine (Carbovir: NSC 614846), a novel nucleoside analog, emerged as a potent and selective anti-HIV agent from a large screening program conducted by the National Cancer Institute and its contractors. Its hydrolytic stability and its ability to inhibit the infectivity and replication of HIV in T-cells at concentrations of approximately 200- to 400-fold below toxic concentrations make carbovir a top-priority candidate for development as a potential antiretroviral agent in the treatment of AIDS patients.",

author = "Robert Vince and Mei Hua and Jay Brownell and Susan Daluge and Fangchen Lee and Shannon, {William M.} and Lavelle, {George C.} and Jeanine Qualls and Weislow, {Owen S.} and Rebecca Kiser and Canonico, {Peter G.} and Schultz, {Robert H.} and Narayanan, {V. L.} and Mayo, {Joseph G.} and Shoemaker, {Robert H.} and Boyd, {Michael R.}",

note = "Funding Information: This work was supported by NIH grant R01 CA23263, NCl contract NO1-CA-74102, and USAMRIID contract DAMD17-86-C-6013.",

year = "1988",

month = oct,

day = "31",

doi = "10.1016/S0006-291X(88)80950-1",

language = "English (US)",

volume = "156",

pages = "1046--1053",

journal = "Biochemical and Biophysical Research Communications",

issn = "0006-291X",

publisher = "Elsevier B.V.",

number = "2",

}

TY - JOUR

T1 - Potent and selective activity of a new carbocyclic nucleoside analog (Carbovir: NSC 614846) against human immunodeficiency virus In vitro

AU - Vince, Robert

AU - Hua, Mei

AU - Brownell, Jay

AU - Daluge, Susan

AU - Lee, Fangchen

AU - Shannon, William M.

AU - Lavelle, George C.

AU - Qualls, Jeanine

AU - Weislow, Owen S.

AU - Kiser, Rebecca

AU - Canonico, Peter G.

AU - Schultz, Robert H.

AU - Narayanan, V. L.

AU - Mayo, Joseph G.

AU - Shoemaker, Robert H.

AU - Boyd, Michael R.

N1 - Funding Information: This work was supported by NIH grant R01 CA23263, NCl contract NO1-CA-74102, and USAMRIID contract DAMD17-86-C-6013.

PY - 1988/10/31

Y1 - 1988/10/31

N2 - Carbocyclic 2′,3′-didehydro-2′,3′-dideoxyguanosine (Carbovir: NSC 614846), a novel nucleoside analog, emerged as a potent and selective anti-HIV agent from a large screening program conducted by the National Cancer Institute and its contractors. Its hydrolytic stability and its ability to inhibit the infectivity and replication of HIV in T-cells at concentrations of approximately 200- to 400-fold below toxic concentrations make carbovir a top-priority candidate for development as a potential antiretroviral agent in the treatment of AIDS patients.

AB - Carbocyclic 2′,3′-didehydro-2′,3′-dideoxyguanosine (Carbovir: NSC 614846), a novel nucleoside analog, emerged as a potent and selective anti-HIV agent from a large screening program conducted by the National Cancer Institute and its contractors. Its hydrolytic stability and its ability to inhibit the infectivity and replication of HIV in T-cells at concentrations of approximately 200- to 400-fold below toxic concentrations make carbovir a top-priority candidate for development as a potential antiretroviral agent in the treatment of AIDS patients.

UR - http://www.scopus.com/inward/record.url?scp=0023791782&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0023791782&partnerID=8YFLogxK

U2 - 10.1016/S0006-291X(88)80950-1

DO - 10.1016/S0006-291X(88)80950-1

M3 - Article

C2 - 2847711

AN - SCOPUS:0023791782

SN - 0006-291X

VL - 156

SP - 1046

EP - 1053

JO - Biochemical and Biophysical Research Communications

JF - Biochemical and Biophysical Research Communications

IS - 2

ER -

Potent and selective activity of a new carbocyclic nucleoside analog (Carbovir: NSC 614846) against human immunodeficiency virus In vitro

Abstract

Bibliographical note

UN SDGs

Publisher link

Find It

Other files and links

Fingerprint

Cite this